Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Premium for Sakigake Products Clears Chuikyo Subcommittee
December 17, 2015
- Survey Finds Unexpectedly Low Market Prices for Injectable Generics; Industry to Accept 50% Rule
December 17, 2015
- Chuikyo Subcommittee OKs Outline of FY2016 Drug Pricing Reform, Rollout of “Huge Seller” Re-Pricing
December 17, 2015
- PMDA Plans to Increase Inspection Staff in Response to Kaketsuken Scandal
December 17, 2015
- Japan to Draw Up Action Plan on Drug Resistance: Health Minister
December 16, 2015
- MHLW to Establish Task Force in Response to Scandal at Kaketsuken
December 16, 2015
- Diet Submission of Clinical Research Bill Expected for Next Year: Panel Member
December 15, 2015
- More than 10 Regenerative Medicine Products Seeking Sakigake Designation: MHLW Official
December 15, 2015
- Chuikyo Discusses Optimizing Health Coverage for Poultices, Vitamins
December 14, 2015
- PMDA Reviewing Use of Ofev in Patients with Liver Dysfunction
December 14, 2015
- LDP OKs Taxation Changes for FY2016; R&D Tax Credit to Remain Intact
December 11, 2015
- 6 Drug Makers to Participate in AMED’s Drug Discovery Consortium
December 11, 2015
- First Generics for Jzoloft, Other Brands to Join NHI Price List on Dec. 11
December 10, 2015
- 3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation
December 10, 2015
- Industry Opposes Expanded Price Cuts under Z2 Rule, Calls for Retention of 60% Pricing Rule for New Injectable, Topical Generics
December 10, 2015
- LDP Budget Debate in Homestretch; Govt Eyes “Huge Sellers”, Generics, Z2 to Squeak Out Funds for Upping Physician Fees
December 9, 2015
- MHLW’s Failure to Detect Kaketsuken’s 40-Year Cover-Up Regrettable: Shiozaki
December 9, 2015
- Editor’s Pick: Five Healthcare Policy News Headlines for November
December 8, 2015
- MHLW Announces Basic Policy for FY2016 Medical Fee Reform
December 8, 2015
- PMDA to Begin Unannounced Regular Inspections in Wake of GMP Violations by Kaketsuken
December 8, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…